- Posts: 799
- Thank you received: 99
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
andre300 wrote: Can someone break this down to a couple of sentences thats in english, preferably
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Oupa wrote: MA
Do you perhaps have any info on how GW can influence menopause ?
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
gab wrote: think ill do 20mg tomorrow just to make sure its the gw.
not taking any other supps right now. maybe its the keto.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
Please Log in or Create an account to join the conversation.
rdopperman wrote: Have u all seen the new info posted on the web about gw501516. Not clear about the cancer development and if it is only on prolonged use.
Any info will help wanted to start on monday but WADA report got me wundering
895 RAT CARCINOGENICITY STUDY WITH
GW501516, A PPAR DELTA AGONIST.
L. E. Geiger1, W. S. Dunsford2, D. J. Lewis2,
C. Brennan3, K. C. Liu3 and S. J.
Newsholme1. 1Safety Assessment,
GlaxoSmithKline, King of Prussia, PA,
2Safety Assessment, GlaxoSmithKline, Ware,
United Kingdom and 3Huntingdon Life
Sciences, Huntingdon, United Kingdom.
GW501516, a non-genotoxic PPARδ agonist,
was assessed for carcinogenic poten- tial by
daily administration (oral gavage) to Han
Wistar rats for a period of 104 weeks. Males
were given 0, 5, 15 or 30 mg/kg/day for the
first 6 weeks of the study. For the
remainder of the study males were given 0,
5, 20 or 40 mg/kg/day. Females were given
0, 3, 10 or 20 mg/kg/day for the entire
study. GW501516 produced test article-
related neoplastic findings in multiple
tissues at all doses. Increased mortal- ity
was seen with females given GW501516 at
all doses and uterine endometrial
adenocarcinoma contributed to death in a
high proportion of these animals.
Neoplasms considered test-article related
occurred in the liver (hepatocellular ade-
noma at ≥ 10 mg/kg/day), urinary bladder
(transitional cell carcinoma in males given
20 and 40 mg/kg/day), thyroid (follicular
cell adenoma at ≥ 3 mg/kg/day and
carcinoma in males at ≥ 20 mg/kg/day),
tongue (squamous cell papilloma in males
at 5 mg/kg/day and 40 mg/kg/day), stomach
(squamous cell papilloma in males at ≥ 5
mg/kg/day and a female at 20 mg/kg/day,
and carcinoma in a male at 40 mg/kg/day
and a female at 3 mg/kg/day), skin
(inverted squamous cell papilloma in males
at ≥ 5 mg/kg/day and females at 3 or 20
mg/kg/day), Harderian glands (ade- noma
in males at ≥ 5 mg/kg/day and
adenocarcinoma in a male at 40 mg/kg/
day), testes (interstitial cell adenoma at 40
mg/kg/day), ovary (Sertoli cell adenoma at
≥ 10 mg/kg/day) and uterus (polyp and
endometrial adenocarcinoma at ≥ 3 mg/kg/
day). Some of the tumor types observed in
this study have not been reported with
either PPARα or PPARγ agonists and may
reflect tumor promotion mediated through
PPARδ agonism.
Please Log in or Create an account to join the conversation.